Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

Andrew Blauvelt, Jacob P. Thyssen, Emma Guttman-Yassky, Thomas Bieber, Esther Serra-Baldrich, Eric Simpson, David Rosmarin, Hany Elmaraghy, Eric Meskimen, Chitra R. Natalie, Zhuqing Liu, Chenjia Xu, Evangeline Pierce, Mary Ann Morgan-Cox, Esther Garcia Gil, Jonathan I. Silverberg

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials'. Together they form a unique fingerprint.

Medicine & Life Sciences